Since
the introduction of acetyl cholinesterase inhibitors as the
first approved drugs by the US Food and Drug Administration for Alzheimer’s
disease (AD) in clinics, less than satisfactory success in the design
of anti-AD agents has impelled the scientists to also focus toward
inhibition of Aβ aggregation. Considering the specific binding
of fragments for their parent peptide, herein, we synthesized more
than 40 new peptides based on a C-terminus tetrapeptide fragment of
Aβ
1–42
. Initial screening by MTT cell viability
assay and supportive results by ThT fluorescence assay led us to identify
a tetrapeptide showing complete inhibition for Aβ
1–42
aggregation. Peptide
20
displayed 100% cell viability
at 20 μM concentration, while at lower concentrations of 10
and 2 μM 76.6 and 70% of cells were viable. Peptide
20
was found to restrict the conformational transition of Aβ
1–42
peptide toward β-sheet structure. Inhibitory
activity of tetrapeptide
20
was further evidenced by
the absence of Aβ
1–42
aggregates in electron
microscopy. Peptide
20
and other significantly active
tetrapeptide analogues could prove imperative in the future design
of anti-AD agents.